Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline.
Endokrynologia Polska（2023）
摘要
CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.
更多查看译文
关键词
pleural fibrosis, pulmonary fibrosis, dopamine agonist, prolactinoma, cabergoline
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要